T

Tianjin Ringpu Bio-Technology Co Ltd
SZSE:300119

Watchlist Manager
Tianjin Ringpu Bio-Technology Co Ltd
SZSE:300119
Watchlist
Price: 18.48 CNY -3.25%
Market Cap: 8.6B CNY
Have any thoughts about
Tianjin Ringpu Bio-Technology Co Ltd?
Write Note

Tianjin Ringpu Bio-Technology Co Ltd
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Tianjin Ringpu Bio-Technology Co Ltd
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
T
Tianjin Ringpu Bio-Technology Co Ltd
SZSE:300119
Net Income (Common)
ÂĄ424m
CAGR 3-Years
-1%
CAGR 5-Years
22%
CAGR 10-Years
16%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Net Income (Common)
ÂĄ3.3B
CAGR 3-Years
8%
CAGR 5-Years
11%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Net Income (Common)
ÂĄ3.1B
CAGR 3-Years
9%
CAGR 5-Years
18%
CAGR 10-Years
23%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Net Income (Common)
ÂĄ5.4B
CAGR 3-Years
-5%
CAGR 5-Years
2%
CAGR 10-Years
14%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Net Income (Common)
ÂĄ4.3B
CAGR 3-Years
5%
CAGR 5-Years
3%
CAGR 10-Years
6%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Net Income (Common)
-ÂĄ780.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Tianjin Ringpu Bio-Technology Co Ltd
Glance View

Market Cap
8.6B CNY
Industry
Pharmaceuticals

Tianjin Ringpu Bio-Technology Co., Ltd. has carved a niche for itself as a formidable player in the animal health and nutrition industry. Founded in 1998, the company has steadily expanded its portfolio, offering a diverse range of products designed to enhance the health and productivity of livestock and pets. Ringpu's operations are tightly integrated across research, development, production, and sales of veterinary vaccines, medicines, and feed additives. By leveraging cutting-edge biotechnology, Ringpu devises innovative solutions that meet the rigorous standards of animal health care. Its research facilities are at the forefront of developing vaccines that guard against prevalent livestock and pet diseases, ensuring that its offerings remain both effective and relevant. The company's ability to generate revenue hinges on its extensive distribution network and the strategic partnerships it has fostered within China and globally. Ringpu sells its products through a well-established sales force that connects with farmers, livestock producers, and veterinary clinics, providing not just products but also comprehensive health management solutions. Additionally, the company invests heavily in fostering relationships with academic institutions and research bodies, ensuring a steady pipeline of groundbreaking discoveries and innovations. This approach not only bolsters the company's reputation in the industry but also guarantees a sustained stream of income as more clients turn to Ringpu for reliable and sophisticated animal healthcare solutions.

Intrinsic Value
24.96 CNY
Undervaluation 26%
Intrinsic Value
Price
T

See Also

What is Tianjin Ringpu Bio-Technology Co Ltd's Net Income (Common)?
Net Income (Common)
424m CNY

Based on the financial report for Sep 30, 2024, Tianjin Ringpu Bio-Technology Co Ltd's Net Income (Common) amounts to 424m CNY.

What is Tianjin Ringpu Bio-Technology Co Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
16%

Over the last year, the Net Income (Common) growth was 9%. The average annual Net Income (Common) growth rates for Tianjin Ringpu Bio-Technology Co Ltd have been -1% over the past three years , 22% over the past five years , and 16% over the past ten years .

Back to Top